The surface fibrillar protein antigen I/II (AgI/II) of Streptococcus mutans is a strongly immunogenic protein when given parenterally and is considered to be a promising candidate for a vaccine against dental caries (31) . For this purpose, it is desirable to elicit a salivary immunoglobulin A (IgA) antibody response, which is most effectively achieved by stimulating the common mucosal immune system (29) . According to this concept, antigens presented at central inductive sites, such as the gut-associated lymphoid tissues (GALT), induce the clonal expansion of specific IgA-committed B cells and appropriate T cells, which then emigrate and ultimately settle in remote effector sites of mucosal immunity, including the salivary glands. Here, terminal differentiation of the B lymphoblasts into polymeric IgAsecreting plasma cells occurs under the control of stimulated T cells, and the product, secretory IgA, is finally released into the external secretion. Like other soluble proteins, AgI/II given alone perorally does not readily induce mucosal or systemic immune responses (8) , probably because it is readily digested and not efficiently taken up by the GALT. However, we have demonstrated that in mice, intragastric (i.g.) administration of microgram amounts of AgI/II conjugated to cholera toxin B subunit (CTB) could induce both serum IgG and IgA antibodies and salivary IgA antibodies to AgI/II, which lasted for at least 6 months (8, 32) . Cholera toxin (CT) is exceptionally effective as an enteric immunogen and adjuvant in experimental animals (6, 7, 11, 20, 24) . Antigens given perorally together with CT induce IgA responses in mucosae and IgG and IgA antibodies in plasma to * Corresponding author. both components. We found that CT was necessary as an adjuvant for AgI/II-CTB conjugates given i.g. in microgram doses and that conjugation of AgI/II to CTB was essential for these doses to induce effective responses to AgI/II in both mucosal and systemic sites (8, 32) . However, the responses varied among animals, and some animals failed to respond even after three doses of 150 ,g of AgI/II-CTB conjugate. Furthermore, it is not feasible to use CT in humans as it is highly toxic, and the ability of nontoxic CTB to act as a mucosal adjuvant has been debated: various results have been obtained, depending upon the antigen, dose, route, and species involved (6, 8, 28, 32, 34, 35, 40) .
Intranasal (i.n.) immunization has been successfully used to induce antibodies to a variety of antigens administered with CTB or CT (1, 30, 34, 35 ELISPOT assay. Total Ig-and specific antibody-secreting cells were enumerated by ELISPOT assay on 96-well membrane-based plates (Millipore Inc., Bedford, Mass.) coated with anti-Ig or with AgI/II or CT, as described previously (32) . Suspensions of viable cells at appropriate concentrations were incubated in duplicate wells for 3 to 4 h, and the plates were developed with isotype-specific goat anti-mouse Ig-peroxidase conjugates (Southern Biotechnology Associates, Birmingham, Ala.). The spots formed with 3-amino-9-ethylcarbazole plus H202 were counted under a stereo microscope and spot-forming cells (SFC) were expressed relative to 106 cells plated.
Collection of fluids. Serum was obtained from tail vein blood or from blood collected from the subclavian veins when mice were sacrificed. Saliva was collected as described previously (32) after stimulation of secretion with carbachol and stored at -20°C.
Gut wash was obtained by flushing the small intestine with 2 ml of Dulbecco's PBS into 3 ml of 50 mM EDTA containing 0.1 mg of soybean trypsin inhibitor (Sigma) per ml, made up to 6 ml, decanted from solid material, vortexed, and centrifuged for 10 min at 650 x g. The top 5 ml was removed, mixed with 50 ,ul of 100 mM phenylmethylsulfonyl fluoride in 95% ethanol, and centrifuged at 27,000 x g for 20 min at 4°C. The top 4 ml was taken, mixed with a further 40 ,ul of 100 mM phenylmethylsulfonyl fluoride and 40 pl of 1% NaN3.
After standing for 15 min, 200 ,ul of FCS was added, and the fluid was stored at -20°C (13) .
Tracheal wash was obtained by opening the exposed trachea to insert a polypropylene cannula, which was tied in place and connected to a syringe. The thorax was opened, avoiding damage to the lungs, and 1 ml of Dulbecco's PBS was injected into the trachea and withdrawn three times. The fluid was stored at -20°C and centrifuged before being assayed. ELISA. Isotype-specific antibodies and total Ig isotype concentrations were determined by ELISA on 96-well plates coated with AgI/II, CT, or isotype-specific anti-Ig, as described previously (32) . The plates were developed with goat anti-mouse IgM-, IgG-, or IgA-peroxidase conjugates (Southern Biotechnology Associates) and 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) substrate with H202.
Unknowns were calculated by interpolation on calibration curves constructed by a computer program based on four parameter logistic algorithms, as previously described (41 
RESULTS
Comparison of i.n. and i.g. routes of immunization. To compare the antibody responses in serum and saliva samples of mice immunized either i.g. or i.n., two groups of mice were immunized with three doses of 15 ,ug of AgI/II-CTB conjugate plus 5 -g of CT by either route at 10-day intervals. Serum anti-AgI/II and anti-CT antibody levels in i.n. immunized mice were raised higher than those in i.g. immunized mice after the initial immunization (Fig. 1) . The peak levels of serum specific IgG (on day 35) and IgA (on day 28) antibodies were significantly higher (P, <0.05) in the i.n. immunized group than in the i.g. immunized group The proportions of salivary IgA antibodies against AgI/II and CT relative to the total IgA concentration, as well as the actual antibody concentrations in saliva, were elevated in both i.n. and i.g. immunized groups (Fig. 2) . The i.n. immunized mice showed significantly higher peak levels (P, <0.005, on day 35) of anti-AgI/II and anti-CT IgA than i.g. immunized mice.
After a single booster immunization about 3 months later, the recall responses were more diverse than after the initial immunization. Only the i.g. immunized group showed substantial serum IgM antibody responses 7 days after the booster immunization (Fig. 1 (Fig. 2) . However, total salivary IgA concentrations as well as specific IgA antibody levels were concordantly increased in both groups (data not shown), as observed previously (32) .
Antibody responses in different secretions after i.n. and i.g. immunization. To compare the distribution of antibody responses after i.n. and i.g. immunization, groups of mice were immunized with AgI/II-CTB and CT according to the previous initial schedules, except that the i.g. dose of AgI/II-CTB conjugate was increased to 30 ,ug in an attempt to make the overall level of responses similar in both groups. Various secretion samples were collected 7 days after the third dose for assay of antibodies, and the associated tissues were excised and processed to obtain MNC for ELISPOT assays.
Salivary IgA antibodies to both AgI/II and CT after i.g.
immunization were enhanced by the increased dose of immunogen (Table 1) , compared with the responses illustrated in Fig. 2 . However, as the concentration of total salivary IgA was greater in the i.n. immunized animals, the actual IgA antibody levels to both antigens appeared to be higher in this group. A marked increase in total salivary IgA Distribution of antibody-secreting cells after i.n. and i.g. immunization. Immunization by the i.n. route induced larger numbers of AgI/II-and CT-specific SFC of all isotypes in the spleen and of IgA isotype in the salivary glands than i.g. immunization (Table 2) . In contrast, i.g. immunization induced stronger IgA SFC responses to AgI/II and especially to CT in LP. When the CLN that drain salivary glands were examined, again substantially larger numbers of AgI/II-and CT-specific SFC of all isotypes were found in i.n. immunized mice than in i.g. immunized mice ( Table 2 ). In MLN, few specific SFC were found, the largest number being cells secreting anti-CT IgA in mice immunized i.g. (Table 2) .
Requirement for coupling Agl/ll to CTB and for CT as an adjuvant in i.n. immunization. Previous experiments (8, 32) demonstrated that responses to i.g. immunization with small doses of AgI/Il and CTB depended upon chemical coupling of AgI/II and CTB and the coadministration of a small adjuvant dose of intact CT. To determine whether the same requirements applied also to i.n. immunization, groups of mice were immunized i.n. with 15 ,ug of AgI/II-CTB conjugate with or without 5 ,ug of free CT or with 10 ,ug of free AgI/II alone or mixed with 5 ,ug of either free CTB or free CT. The mice were immunized three times at 10-day intervals. IgA antibody responses were determined in samples of saliva taken 7 days after each immunization and 14 days after the third dose (Fig. 3) . The strongest anti-AgI/II IgA responses were given by mice immunized with AgI/II-CTB conjugate, with or without free CT, and no difference between these two groups was discernible. Lower, but still strong, responses were also shown in mice given AgI/II mixed with either free CTB or free CT, and again there was no difference in response between these two groups. Mice immunized with AgI/II alone gave clearly detectable, though substantially lower, salivary IgA responses. One-way analysis of variance of the responses at day 35 indicated significant differences between i.n. immunization with AgI/II-C7B conjugate and AgI/II plus free CTB, AgI/II-CTB conjugate plus free CT and AgI/II plus free CT, and AgI/II alone and all other combinations. Thus, free CT had no enhancing effect for AgI/II-CTB conjugates given i.n., but either free CT or free CT'IB could enhance responses to free AgI/II. However, immunization with AgI/II-CTB conjugate i.n. gave the strongest salivary IgA responses.
Salivary IgA anti-CT responses were highest in animals receiving free CT, irrespective of other components, and lower in mice given free or combined CTB without free CT (Fig. 3) adjuvant, although the mean levels of anti-AgI/Il IgG tended to be higher on day 35 in mice given AgI/II plus free CT or free CTB as adjuvant (Fig. 4) . As expected, the serum IgG and IgA responses to CT were significantly stronger in mice given free CT irrespective of other immunogen components (data not shown).
Anamnestic responses to AgI/I and CT in i.n. immunized mice. Previous experiments (32) have shown that i.g. immunization with AgI/I-CTB conjugate and free CT did not establish significant capacity to mount anamnestic responses in salivary IgA antibodies to AgI/II in response to a single subsequent immunization. A similar result was found after i.n. immunization with AgI/II-CTB conjugate and free CT (see above). However, i.g. immunization did prime mice for substantial recall serum antibody responses to both AgI/Il and CT (32) . To determine whether the different regimens of i.n. immunization varied in their abilities to induce anamnestic antibody responses, the same animals were given a single booster immunization of the same material and dose about 3 months later when responses to the initial immunizations had declined, and serum and saliva samples were collected 7 and 14 days later.
Peak serum IgM and IgA recall responses, measured at 7 days after booster immunization, to AgI/I1 were significantly greater (P, <0.01 for IgM; P, <0.05 for IgA; paired Student's t test) than initial responses only in groups given AgI/II plus free CT or free CTB (Fig. 4) . In contrast, mice given AgI/II-CTB conjugate, with or without free CT, showed lower peak recall IgM, IgG (at 14 days), and IgA responses (P, <0.05 for all isotypes) compared with those obtained after initial immunization (Fig. 4) , and mice immunized with AgI/Il plus free CT or free CTB gave lower recall IgG responses, though these were not statistically significant (Fig. 4) . Thus, it appears that enhanced anamnestic serum IgG antibody responses to AgI/II were not elicited by i.n. immunization. There were no specific increases in salivary 
Downloaded from
IgA antibodies relative to total IgA concentrations after i.n. booster immunization, but total salivary IgA levels were increased in all groups (data not shown), as observed previously (see above) and after i.g. booster immunization (32) .
DISCUSSION
Parallel experiments showed clearly that after three simi- (8, 16, 24, 32) , it was apparently successful in others (6, 40) , especially when coupled to the antigen (2, 9, 28 
